Use this link to cite:

http://hdl.handle.net/2183/32966

Approved and off-label uses of obesity medications, and potential new pharmacologic treatment options

Thumbnail Image

Files

IsidroML_Approved.pdf (261.41 KB)

Identifiers

URI: http://hdl.handle.net/2183/32966

Publication date

2010-01-12

Authors

Isidro, María Luisa

Advisors

Other responsabilities

Journal Title

Bibliographic citation

Isidro ML, Cordido F. Approved and off-label uses of obesity medications, and potential new pharmacologic treatment options. Pharmaceuticals (Basel). 2010 Jan 12;3(1):125-145.

Type of academic work

Academic degree

Abstract

[Abstract] Available anti-obesity pharmacotherapy options remain very limited and development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase energy expenditure. This review will focus on approved obesity medications, as well as potential new pharmacologic treatment options.

Description

Review

Keywords

Drug treatment Ghrelin Leptin Obesity Orlistat Sibutramine Rimonabant

Editor version

https://doi.org/10.3390/ph3010125

Rights

Creative Commons Attribution 3.0 International License (CC-BY 3.0)

Collections

Investigación (FCS)
Creative Commons Attribution 3.0 International License (CC-BY 3.0)

Except where otherwise noted, this item's license is described as Creative Commons Attribution 3.0 International License (CC-BY 3.0)